EU/3/20/2295: Orphan designation for the diagnosis of insulinoma



On 26 June 2020, orphan designation EU/3/20/2295 was granted by the European Commission to Stichting Katholieke Universiteit, Netherlands, for Lys40(NODAGA-68Ga)NH2-exendin-4 for the diagnosis of insulinoma.

Key facts

Active substance
Intended use
Diagnosis of insulinoma
Orphan designation status
EU designation number
Date of designation

Stichting Katholieke Universiteit
Reinier Postlaan 2
6525 GC Nijmegen Gelderland
Tel. +31 2436 67243

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating